Otsuka Says Wockhardt's ANDA Infringes Abilify Patent
Law360, New York (November 1, 2013, 9:27 PM EDT) -- Otsuka Pharmaceutical Co. Ltd. sued Wockhardt USA LLC in New Jersey federal court Thursday for infringing its patent for Abilify, after the generics maker submitted an abbreviated new drug application for its own version of the schizophrenia and depression drug before the patent expires.
The Japanese drugmaker alleges that Switzerland-based Wockhardt Bio AG, through its U.S.-based subsidiary Wockhardt USA, submitted an ANDA to the U.S. Food and Drug Administration that infringes U.S. Patent Number 6,977,257.
"Wockhardt's generic product will, if approved and marketed, infringe at least one claim of the '257 patent," the complaint says.
According to the complaint, the patent,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!